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1. Introduction
Autoimmune liver disease (AILD) consists of autoimmune hepatitis (AIH), primary biliary
cirrhosis (PBC) and primary sclerosing cholangitis (PSC). It is characterised by the immune
mediated injury to the hepatocytes and bile ducts. Hepatocyte injury is the predominant
features in autoimmune hepatitis and biliary injury is the hallmark of primary biliary cirrhosis
(Intrahepatic bile duct injury), primary sclerosing cholangitis or Immunoglobulin (Ig) G4
mediated cholangitis (both intra and extra-hepatic bile duct injury). Overlap or variant
syndrome indicates the presence of simultaneous injury to both hepatocytes and cholangio‐
cytes during the course of the disease. Imbalance in effector and regulatory arm of adaptive
immune cells had been described as the immunopathogenesis of AILD. Antigenic causative
factors are still poorly understood across AILD but genetic, environmental factors and
microbiota play a major role in disease pathology.
1.1. Aims
The aim of the chapter is to describe in depth of each disease entity in regard to their immuno-
pathogenesis, diagnosis, investigations and management strategies including standardised
care as well as future novel therapies.
1.2. Concerns
Long term global immunosuppressive therapy in AIH with multiple side effects and lack of
definitive treatment to tackle the underlying immunopathology in PBC and PSC are major
challenging aspects in AILD. Thorough understanding of causative antigens, immuno-
pathogenesis, OMIC profiles (genomic, metabolomics, proteomic and microbiomic) of AILD
patients will direct clinicians for stratification and individualized personal care. Novel new
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immunological based cell and cytokines therapies are urgently warranted in defined unique
group of AILD patients.
The diagnosis and management of AILD can be constantly challenging due to the presence of
overlap features at diagnosis or gradual evolution in phenotype of diseases from one spectrum
(typical AIH) to others (overlap of AIH/PBC and AIH/PSC) during the disease process.
Therefore, the continuous assessment of the disease presentations are essential in follow up of
patients with AILD.
2. Background
An autoimmune liver disease (AILD) is an umbrella term for diseases caused by immune
mediated reaction to either hepatocytes or bile ducts. Regulatory T cells (Treg) play an
important and essential role in the maintenance of homeostasis and prevention of autoimmune
responses [1]. Autoimmune hepatitis (AIH) is caused by an immune mediated injury of the
hepatocytes and characterised by presence of lobular and interface hepatitis on liver histology,
presence of hypergammaglobulinaemia and high titre of antinuclear antibodies (ANA) in the
serum with transaminitis on liver biochemistry. The main aim of treatment is to suppress the
immune system globally and the first line therapies used are prednisolone and azathioprine.
Second line therapies such as tacrolimus and mycophenolate mofetil are also used in AIH
patients. Two commonly used biologics in difficult-to-treat AIH patients are anti- tumour
necrosis factor (anti-TNF) for example Infliximab and anti-CD20 monoclonal antibody therapy
as in Rituximab. New novel antigen-specific autologous regulatory T cells therapy develop‐
ment is also in progress for future treatment of autoimmune hepatitis.
Primary biliary cirrhosis (PBC) is an injury to the intra-hepatic biliary ducts and tends of
present in 4th to 6th decade of life. The main therapy is ursodeoxycholic acid (UDCA) but new
therapies for PBC such as Obeticholic acid have been emerged recently. Patients with PBC tend
to suffer with significant itch and management of itch can be challenging at times. There are
therapies available for itch from the spectrum to cholestyramine to immunoglobulins infusion
treatment.
Primary sclerosing cholangitis (PSC) is an immune mediated injury, mainly to biliary system
either intrahepatic or extrahepatic or both. PSC is common in young, male patient and
commonly associated with inflammatory bowel disease (IBD), especially ulcerative colitis.
There is a significant risk of developing cancer such as cholangiocarcinoma or gall bladder
cancer or bowel cancer in these groups of patients and hence surveillance is important. There
are no targeted treatments available for PSC and liver transplantation is necessary in end stage
PSC.
Detailed summary of three autoimmune liver disease (autoimmune hepatitis, primary biliary
cirrhosis and primary sclerosing cholangitis) are documented in table 1.
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  AUTOIMMUNE 
HEPATITIS (AIH) 
PRIMARY BILIARY 
CIRRHOSIS (PBC) 
PRIMARY SCLEROSIS 
CHOLANGITIS (PSC) 
AGE  Any age  Any age, common over 
40 years 
Around 40 years of age 
GENDER  Female predominance 
(4:1)  
 
Female predominance 
(9:1) 
Male predominance 
(7:3) 
ASSOCIATED 
CONDITIONS 
Other autoimmune 
conditions, commonly 
thyroid disorders, 
diabetes mellitus, coeliac 
disease and 
inflammatory arthritis 
Other autoimmune 
conditions, commonly 
thyroid disorders, 
diabetes mellitus, coeliac 
disease and 
inflammatory arthritis 
 
Inflammatory bowel 
disease, mainly 
ulcerative colitis 
TRANSAMINASE 
LEVELS (ALT OR AST) 
Raised (>5x ULN) 
 
 
 
Raised (stable)  Raised (fluctuating) 
ALP OR GGT  Raised 
 
 
 
Raised (stable)  Raised (fluctuating)‐ (> 3 
fold increase) 
 
IMMUNOLOGICAL 
PROFILE 
Raised ANA, ASMA or 
LKM 
Raised Ig G 
Raised AMA (anti‐gp 
210, anti‐Sp 100) 
Raised Ig M 
None 
BILIARY 
INVOLVEMENT 
 
No  Yes (small duct)  Yes (small to large duct) 
LIVER HISTOLOGY [1] 
INTERFACE HEPATITIS 
PORTAL 
INFLAMMATION 
GRANULOMAS 
 
 
Yes 
Lymphoplasmacytic 
infiltrate 
No 
 
May be 
Lymphocytic infiltrate 
 
Yes 
 
May be 
Lymphocytic infiltrate 
 
Rare (<10% of cases) 
RESPONSE TO 
STEROIDS/ OTHER 
IMMUNOSUPPRESIONS 
 
Yes  No  No 
RESPONSE TO 
UROSDEOXYCHOLIC 
ACID (UDCA) 
 
No  Yes  Maybe 
PROGNOSIS  If untreated, patient have 
poor prognosis with 5 
and 10 year survival 
rates of 50 and 10% [2]. 
 
Prognosis is excellent in 
patients who achieved 
biochemical response 
with UDCA therapy 
Median survival without 
transplantation is 12 to 
15 years [3] 
ANA: Anti-nuclear antibodies, ASMA: anti smooth muscle antibodies, LKM: Liver- kidney-microsomal antibodies, g G:
Immunoglobulin G, Ig M: Immunoglobulin M, Anti-gp 210: Antibodies against the nuclear pore membrane glycoprotein
(anti-gp210), Anti-Sp 100: Antibodies against the nuclear protein Sp100, ULN: Upper limit of normal, UDCA: Ursodeox‐
ycholic acid
Adapted from 1) Trivedi, P.J. and G.M. Hirschfield, Review article: overlap syndromes and autoimmune liver disease.
Aliment Pharmacol Ther, 2012. 36(6): p. 517-33. 2) Strassburg, C.P. and M.P. Manns, Therapy of autoimmune hepatitis. Best
Pract Res Clin Gastroenterol, 2011. 25(6): p. 673-87.3) Yimam, K.K. and C.L. Bowlus, Diagnosis and classification of
primary sclerosing cholangitis. Autoimmun Rev, 2014. 13(4-5): p. 445-50.
Table 1. Summary of Autoimmune liver disease
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3. Autoimmune hepatitis
3.1. Epidemiology
Autoimmune hepatitis (AIH) is an immune mediated, chronic inflammatory disease of
unknown aetiology, mainly affecting the hepatocytes. It was first defined in 1950 by Walden‐
ström when he described a chronic hepatitis in young woman which eventually lead to liver
cirrhosis [2]. It is characterised by the morphological changes of interface hepatitis on liver
biopsy, hypergammaglobulinaemia and the presence of high circulating ANA in the serum [3,
4]. It is more common in women (around 75%) and can affect at any age from young to elderly.
It is also associated with other autoimmune conditions such as hypothyroidism, ulcerative
colitis, type 1 diabetes mellitus, rheumatoid arthritis, coeliac disease or skin disorders such as
vitiligo. Therefore, obtaining a detailed history especially family history of autoimmune
conditions are important in the assessment of patients with potential AIH diagnosis.
There is limited evidence regarding the incidence and prevalence of AIH. From the data so far,
it has been estimated that the prevalence of AIH is around 5 to 20 cases per 100,000 among the
Caucasian population in Western Europe [5]. AIH accounts for up to 20% of chronic hepatitis
among the Caucasian population of North America and Western Europe [5]. AIH prevalence
and clinical expression appear to vary according to ethnicity. Previous studies showed that
black patients tend to have more aggressive disease [6] whereas Hispanic populations had a
higher prevalence of cirrhosis [7]. Asian patients develop the disease later in life and have a
poorer survival [7] and Alaskan native patients presented more frequently with acute AIH [8].
Clinically, there are three forms of AIH. Type 1 AIH is common in adults and characterised
by the presence of ANA and/or anti smooth muscle antibodies (ASMA) with raised Immuno‐
globulin-G (Ig G). Type 2 is seen mostly in children and characterised by the presence of anti-
liver-kidney-microsomal (LKM) antibodies directed against cytochrome P450 (CYP-2D6) [9,
10] and with lower frequency against UDP-glucuronosyltransferases (UGT) [2, 11]. Antibodies
against soluble liver or liver-pancreas (SLP) antigens are common in type 3 AIH. Around 19%
of patients can present with seronegative disease at the time of diagnosis [12].
3.2. Pathogenesis
The exact aetiopathogenesis of AIH is still unknown. It is a complex process interlinking
environmental and genetic factors in a susceptible host. The most common environmental
trigger thought to cause AIH is viral infection. Drug induced AIH is a recognised entity and
the commonly associated drugs are anti-TNF treatment such as Adalimumab, antibiotics such
as minocycline or nitrofurantion or statins such as rosuvastatin [13-15]. Both T cells and B cells
play an important role in the adaptive immune response to both self and non-self-antigen. T
cells, both CD4 and CD8 T cells, play a major role in the immnuopathogenesis with effector
responses mediated by Natural Killer (NK) cells and macrophages [16]. Regulatory T cells
(Treg) play an essential role in the homeostasis and prevention of autoimmune conditions [1].
They are classified as CD4+ CD25high CD127Low and represent the 2 % of the CD3 subset [17].
Foxp3 (forkhead box P3) is a transcription factor which controls the phenotype, development
and function of Treg [18]. Commitment to Treg lineage primary occurs in the thymus as a result
of presenting self- antigens by medullary thymic epithelium. In AIH, the number of Tregs is
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normal but their function is impaired [19]. Reduction in frequency of Treg has also been
reported [17, 20].
Type 1 AIH is associated with human leukocyte antigen (HLA) DR3 (HLA-DRB1*0301) and
DR4 (HLA-DRB1*0401) in white North Europe and North American patients [21, 22]. It has
been suggested the presence of DR3 is associated with poorer response to treatment and hence
requires liver transplantation (LT) [21, 22]. On the other hand, patients with DR4 are usually
older and more responsive to treatment with steroid [21]. A recent geno-wide association study
of type 1 AIH in Netherlands showed that type 1 AIH is associated with the rs3184504*A allele
in the SH2B3 gene [22]. These single nucleotide polymorphisms (SNP) represent the first
genetic AIH locus outside the Major Histocompatibility Complex (MHC) region [22]. It
encodes a missense variant in exon 3 of the Scr homology 2 adaptor protein 3 (SH2B3) genes
located in the 12q24 region [22]. SH2B3 is a negative regulator of T-cell activation, tumour
necrosis factor, and Janus kinase 2 and 3 signalling, and plays an essential role in normal
haematopoiesis [22]. Capcase recruitment domain family member 10 (CARD 10) gene with
allele rs6000782 has been shown to be associated with type 1 AIH [22]. CARD 10 is a scaffold
protein and induces pro-inflammatory nuclear factor kB activation and it is widely expressed
in a variety of non-haematopoietic tissue including hepatocytes [22].
Proposed pathway of pathogenesis in AIH has been shown in Figure 1.
3.3. Clinical presentations and diagnosis of AIH
Most patients present with nonspecific symptoms such as fatigue, arthralgia and anorexia at
the time of presentation. About 25% of patient present asymptomatically [23] and the majority
of patients present late with symptoms of portal hypertension and decompensated cirrhosis.
Recent systematic review mentioned that around 25 % of elderly patients (age 60 to 65) were
more likely to present asymptomatically, they are more likely to be HLA-DR4 positive and
cirrhotic at initial presentation [24]. They are less likely to be HLA-DR3-positive and to relapse
after treatment withdrawal after complete remission [24]. AIH can also present during
pregnancy or postpartum period. Physical examination can either be normal, or show
hepatomegaly, splenomegaly or signs of chronic liver disease. In some patients, AIH present
as acute severe hepatitis and rarely, they progress to fulminant form and require liver
transplantation [2].
Blood tests can show signs of hepatitis with raised alanine transaminase (ALT, U/L) (usually
less than 500 U/L), aspartate transaminase (AST, U/L) and occasionally bilirubin (umol/L).
Typical immunology profile in AIH patients are raised Ig G with positive ANA, ASMA (in
type 1 AIH) and LKM (in type 2 AIH). Patients with acute presentation of AIH should be
monitored for synthetic function such as international normalised ratio (INR) and albumin as
well as mental status or sign of hepatic encephalopathy since some patients can progress to
acute liver failure rapidly and will need liver transplantation. Viral hepatitis, toxins, drugs
should be excluded in patient presenting with acute or chronic form of hepatitis. Men with
AIH appear to have a higher relapse rate and younger age of disease onset [25, 26]. Cirrhosis
at presentation [27, 28] and presence of SLA antibodies are poor predictive outcomes in type
1 AIH patients [29, 30].
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Liver biopsy is recommended at the time of presentation to establish the diagnosis as well as
to guide the treatment, however in patients presenting with acute hepatitis who has suspicious
diagnosis of AIH, the treatment should not be delayed [31]. The histological hallmarks of AIH
is a lymphoplasmacytic peri-portal infiltrate invading the limiting plate, also called piecemeal
necrosis or “interface hepatitis” and eventually lead to lobular hepatitis (Figure 2) [13]. Patients
with chronic AIH usually have plasma cell- rich mononuclear infiltrate involving portal and
peri-portal regions [16] which subsequently lead to peri-portal fibrosis. Up to 30% of patients
with AIH had histological features of cirrhosis at the time of presentation [2]. In 17% of patients
with peri-portal hepatitis whereas 82% of patients who had bridging fibrosis, cirrhosis
develops within 5 years [2].
The diagnosis of AIH is based on multiple investigations and diagnostic criteria was proposed
by the international AIH group in 1993 and subsequently updated in 1999 (Table 2) [13, 32,
CXCL: chemokine (C-X-C motif) ligand 1, CTLA-4: Cytotoxic T-lymphocyte-associated protein 4, CD: Cluster of Differ‐
entiation, CXCR: C-X-C chemokine receptor type, FOXP3: Forkhead box P3, IL: Interleukin, NK: Natural killer, T-reg: T
regulatory cells, TNF: Tumour necrosis factor, IFN: Interferon, Th: T helper.
Figure 1. Pathogenesis of Autoimmune hepatitis. Autoimmune hepatitis (AIH) is initiated by the presence of auto
antigen peptide onto antigen presenting cells (APC) which activates T helper cells (Th0) due to interleukins (IL) 2 and
4. Upon activation of Th0, it can differentiate into Th1 and Th2 cellular pathway. Th1 produces IL2 and Interferon-
gamma (IFN-r) which subsequently activates CD8 lymphocytes.
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33]. In 2008, the groups established the simplified scoring system which is more user friendly
in day to day clinical care[13] (Table 3). The scoring is based on combination of the serum
immunoglobulins titres (ANA, SMA or LKM), serum liver enzymes and liver histology
features with absence of viral hepatitis.
Figure above showed lobular inflammation with 
mainly plasma rich infiltrates (black arrow) and central 
peri‐venulitis (black star) 
Figure above showed interface hepatitis with rich plasma 
cell infiltrates (large arrow head). 
 
Figure 2. Histology findings of autoimmune hepatitis
Clinical features Score
Female +2
ALP:AST ratio
• <1.5
• 1.5-3.0
• >3.0
+2
0
-2
Serum globulin or Ig G above normal
• >2.0
• 1.5-2.0
• 1.0-1.5
• <1.0
+3
+2
+1
0
ANA, SMA or LKM 1
• >1:80
• 1:80
• 1:40
• <1:40
+3
+2
+1
0
Illicit drug use
• Positive
• Negative
-4
+1
Average daily alcohol intake
• <25g/day +2
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Clinical features Score
• >60g/day -2
Histological findings
• Interface hepatitis
• Lymphoplasmacytic infiltrate
• Rosette formation
• None of the above
• Biliary changes
• Other changes
+3
+1
+1
-5
-3
-2
+2
Other autoimmune disease
AMA positivity -4
Viral hepatitis markers
• Positive
• Negative
-3
+3
Definite AIH
Probable AIH
>15
10-15
ALP: alkaline phosphatase, AST: Aspartate transaminase, Ig: Immunoglobulin, ANA: Antinuclear antibodies, SMA:
Smooth muscle antibodies, LKM: Liver kidney microsomal antibodies, AMA: Anti-mitochondrial antibod
Table 2. Revised International Autoimmune Hepatitis Group Scoring System for the Diagnosis of Autoimmune
Hepatitis (AIH) (Adapted from Alvarez et al [21] and Chandok et al [22])
Variables Cut off Points
ANA or SMA ≥ 1;40 1
≥ 1:80 2
Or LKM 1 ≥ 1:40 2
Or SLA Positive 1
Ig G >upper limit of normal 1
>1.1x upper limit of normal 2
Liver histology Compatible with AIH 1
Typical of AIH 2
Absence of viral hepatitis Yes 2
ANA: anti-nuclear antibodies; SMA: anti-smooth-muscle antibodies; LKM1: liver/ kidney microsomal antibody type 1;
SLA: anti-soluble liver antigen.
Definite AIH: A cumulative score ≥7
Probable AIH: A cumulative score =6
Liver histology typical of AIH: interface hepatitis, emperipolesis, hepatic rosette formation
Liver histology compatible with AIH: chronic hepatitis with lymphocytic infiltration, without typical features.
Table 3. Simplified scoring system for autoimmune hepatitis
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4. Management/treatment
4.1. Standard therapy
The main aim for treatment of AIH is to suppress the ongoing inflammation and the first line
therapies used are steroids (either prednisolone or budesonide) with or without azathioprine
(AZA). Steroid side effects such as cosmetic changes, osteopenia, hirsutism, steroid induced
diabetes are seen in about 44% of patients within 12 months of treatment and 80% within 24
months of treatment [2]. Budesonide is a preferred choice of treatment for patients who do not
tolerate prednisolone due to side effects and in patients with diabetes mellitus. It is a synthetic
steroid with high first-pass metabolism in the liver, which is in principle capable of limiting
systemic side effects compared to conventional steroids [2]. Due to those side effects mentioned
above, the adherence to medication can be an issue and hence, compliance needs to be
monitored throughout the treatment period. Patients who need long term steroid therapy (>
3 months) should be started on calcium and vitamin D3 supplements to prevent osteoporosis.
The combination regimen of prednisone and azathioprine is associated with a lower occur‐
rence of corticosteroid-related side effects than the higher dose prednisone regimen (10%
versus 44%), and it is the preferred treatment in patients with AIH. AZA side effects include
abdominal discomforts, pancreatitis, nausea, cholestatic hepatitis, rashes and leukopenia and
they can be seen in 15% of patients who received 50mg of AZA [2]. Azathioprine metabolite
and Thiopurine S-Methyl Transferase (TPMT) levels will guide the optimal dose for individual
patients. Some patients who cannot tolerate AZA benefit from Mercaptourine. The metabolism
of AZA has been demonstrated in Figure 3.
 
 
 
Liver 
Erythrocyte 
Aza: Azathioprine, MP: Mercaptopurine, TIMP: Thiosine 5 mono phosphate, MMP: Methyl mercaptopurine, MMR:
Mehty mercaptopurine ribonucleotides, TU: Thiouric acid, TGN: Thioguanine nucleotide. TPMT: Thiopurine S-methyl
transferase, XO: Xanthise oxidase, IMPDH: Inosine monophosphate dehydrogenase, HPRT: Hypoxanthine phosphori‐
bosyltransferase
(Adapted from Dubinsky, M.C., et al., Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mer‐
captopurine or azathioprine. Am J Gastroenterol, 2003. 98(5): p. 1058-63)
Figure 3. Azathioprine metabolism
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Around 90% of adult patients respond to therapy within first 2 weeks with improvement in
serum immunoglobulins and liver enzymes levels [31]. Treatment should be continued until
normalisation of serum immunological and, biological parameters as well as improvement in
liver histology. Relapsed AIH is characterized by an increase in the serum aminotransferase
levels to at least threefold normal and it occurs in 50% to 86% of patients who previously had
complete remission of their disease and usually happens during the first 6 months after the
termination of therapy [13, 31]. In patients who has sub-optimal response to initial therapy or
relapsed AIH should be considered for more potent treatments such as tacrolimus or myco‐
phenolate mofetil.
4.2. Alternative and future therapies
Alternative therapies include tacrolimus, mycophenolate mofetil (MMF), cyclosporine,
methotrexate, cyclophosphamide, ursodeoxycholic acid (UDCA), infliximab and rituximab
[14]. Although there are some encouraging results with each of the medications, the treatment
has not been implemented into standard management due to lack of randomised control data.
Most of the evidence is based on from small, retrospective, single centre case series [34].
Therefore, these treatments should be only commenced in the specialised centre with presence
of experienced hepatologists.
Cyclosporine A is a lipophilic cyclic peptide of 11 residues produced by Tolypocladium
inflatum that acts on calcium dependent signalling and inhibits T cell function via the inter‐
leukin 2 gene [2]. Use of cyclosporine is limited due to its side effects of hirsutism, hypertension,
renal insufficiency, hyperlipidaemia, increased risk of infection and malignancy [2]. The
evidence of cyclosporine in adult AIH is limited due to a small number of case series arising
from single centres. In one study of six patients, cyclosporine normalised ALT in all patients
and 3 patients had improvement with liver histology in follow up. Another study of 5 patients
with cyclosporine treatment showed biochemical improvement in 4 patients who had not
responded to standard therapy [35]. In a study of 8 patients, it showed that cyclosporine is safe
and all patients achieved remission [36].
Tacrolimus (Tac) is a macrolide compound and its mechanism is similar to that of cyclosporine
A but it binds to a different immunophilin [2]. The main side effect is renal toxicity. Both
cyclosporine and tacrolimus are calcineurin inhibitors and can be used as a rescue therapy for
difficult to treat AIH patients. Compliance can be monitored by drug level in both drugs. An
open label preliminary study in which 21 AIH patients were treated with tacrolimus (Tac)
showed reduction of liver enzymes (ALT and AST) in 70-80% of patients who received 3
months of therapy [37]. There are only few studies reported use of Tac in the treatment of AIH
although wide experience use of this drug exist in cohort of AIH patients who had liver
transplantation (LT) [34]
Mycophenolate Mofetil (MMF) is a non-competitive inhibitor of inosine monophosphate
dehydrogenase, which blocks the rate-limiting enzymatic step in de novo purine synthesis.
MMF has a selective action on lymphocyte activation, with marked reduction of both T and B
lymphocyte proliferation [2]. Many patients experience headache, nausea, diarrhoea, dizziness
and neutropenia with MMF therapy [14]. It is contraindicated in pregnancy due to its terato‐
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genic side effects. Recent studies of 59 patients with treatment naïve AIH were treated with
MMF and prednisolone as a first line therapies in which the study showed biochemical and
immunological parameters improvements in 88% of patients in the first 3 months and 12% had
partial response [38]. A study from Canadian group studied 16 patients who failed conven‐
tional therapy were given either tacrolimus or MMF [39] and complete response were seen in
50% of patients and 12.5 % had non response to treatment [39]. Another study looking at 36
patients with AIH who were treated with MMF and it showed remission in 39% of patients.
The study mentioned in patients who does not respond to AZA, around 75% of those do not
respond to MMF either [40].
Infliximab, a recombinant humanized chimeric antibody, has been used in other immuno‐
modulatory conditions such as rheumatoid arthritis and inflammatory bowel disease.
However, infliximab has been associated with de novo AIH in some patients with liver
transplantation (LT) and therefore, it should be used by the experienced team in specialised
centre. A retrospective, single centre review of 11 patients with difficult to treat AIH were
treated with infliximab and it showed infliximab led to reduction of inflammation, evidenced
by a decrease in transaminases and serum immunoglobulins [41].
Rituximab is an anti-CD20 chimeric monoclonal antibody, a surface marker expressed on B
cells, from early pre-B to memory B lymphocytes [42]. Treatment with rituximab leads to B cell
depletion through both complement- and antibody-dependent cellular cytotoxicity [42]. AIH
is considered to be a T-cell–mediated disease; however, numerous observations would suggest
that B cells are also involved in its pathogenesis [43]. Although there were good evidences to
suggest that rituximab is effective in autoimmune haemolytic anaemia, cryoglobulinemia and
systemic lupus erythematosus, the data on efficacy of rituximab in AIH are limited [44-46]. A
study by Burak and colleague showed that Rituximab is well tolerated with no significant side
effects and resulted in biochemical response in patients with refractory or intolerant to other
treatment [47].
5. Prognosis
Patients with acute, severe AIH who are untreated have poorer short and long term survival
compared to treated AIH patients [48-50]. For patients with the severe acute phenotype of AIH,
failure to respond to treatment within the first 7–14 days after presentation is associated with
a mortality of almost 50% [51]. For patients with established cirrhosis at presentation, treatment
can induce remission and improve long-term outcome, with 10-year life expectancies of greater
than 90% [52, 53]. Patient with cirrhosis due to AIH usually develop hepatocellular carcinoma
at a mean of 9 to 10 years according to previous published case series and hence, routine
surveillance with 6 monthly ultrasound scan and alpha feto protein (AFP) is recommended
for these cohort of patients [54, 55]. Autoimmune hepatitis is an acceptable reason for liver
transplantation, with frequency of survival exceeding 75% at 5 and 10 years after transplant
[56, 57]. In summary, the overall prognosis of AIH is good for patient who are treated and
responded to immunosuppressive therapy. Therefore, compliance is important which can be
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achieved by supporting patient and education to the patient. It is also crucial to recognise and
treat the patients who are not responsive to standard immunosuppressive therapies with more
novel treatments. It is essential to have smooth handover and transition between paediatric
and adult hepatology team which will help young patients with AIH to continue with their
treatment and follow up.
6. Primary biliary cirrhosis
6.1. Epidemiology
Primary biliary cirrhosis (PBC) is an autoimmune condition and causes a chronic and pro‐
gressive destruction of intrahepatic bile ducts resulting in chronic cholestasis, portal inflam‐
mation, fibrosis and then gradually lead to cirrhosis and liver failure [58]. The disease is
predominantly seen in women than men with a ratio of 10:1 [60] and had a prevalence of 1 in
1000 women over the age of 40 [59].
The highest prevalence and incidence rates have been reported in Great Britain, Scandinavia
and the northern Midwest region of the USA [5, 61]. It has been suggested that the incidence
of PBC is rising and in the United Kingdom (UK), the incidence rate rose from 2.05 cases per
100,000 populations per year in Sheffield from 1980 to 1999 [5, 62] and from 1.1 to 3.2 cases per
100,000 population per year in Newcastle- Upon- Tyne from 1976 to 1994 [63, 64].
6.2. Pathogenesis
Both genetic and environmental factors such as chemical substances, bacterial and viruses play
an important role in the pathogenesis of PBC. In general, data indicate that 1 to 6% of PBC
cases have at least one other family member presenting with the disease [60]. The concordance
rate observed among monozygotic twins for PBC is 63%, among the highest reported in
autoimmune diseases [60]. Prior to the advent of genome-wide association studies, only class
II HLA loci (HLA-DRB1*08, *11, and *13) had been reproducibly shown to associate with
disease [59]. With the application of genome-wide technology, HLA was confirmed as the
strongest association and many other risk loci have been identified, with equivalent effect size
to HLA, including IL12A, IL12RB2, STAT4, IRF5-TNPO3, 17q12.21, MMEL1, SPIB, and CTLA-4
[59]. These collectively support an important role for innate and adaptive immunity in
development of disease [59].
There is an increased auto reactive CD4 pyruvate dehydrogenase complex (PDC)-E2 specific
T cells in liver and regional lymph nodes in patients with PBC and CD8 PDC-E2 T cells
infiltrates in the liver suggesting that anti-mitochondrial response is either directed to the
aetiology or associated with other environmental or genetic trigger [65].
6.3. Clinical presentations and diagnosis
The majority of patients are asymptomatic at the time of diagnosis. With progression of the
disease, patients usually develop fatigue and pruritus. Fatigue is the most common symptom
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and is present in up to 78% of patients with PBC [65]. Fatigue is not associated with disease
severity or disease duration or histological findings and it is difficult to manage in most
patients. Pruritus is a more specific symptom of PBC than fatigue and formerly occurred in
20%-70% of patients with PBC [65]. It can be local or diffuse, usually worse at night and tend
to be in the palms and soles of the feet. Pruritus is often exacerbated by contact with wool,
other fabrics, heat, or during pregnancy [65]. Sicca syndrome, hypothyroidism, vitamin D
deficiency, osteopenia and hypercholesterolemia are commonly seen in patients with PBC and
should be investigated and managed appropriately.
Individuals with abnormal cholestatic liver function tests such as raised alkaline phosphatase
(ALP), gamma glutamyl transferase (GGT) and elevated conjugated bilirubin should be
investigated for underlying PBC [66]. Immunologically, the majority of patients (around 95%)
have positive anti-mitochondrial antibodies (AMA) in their serum and raised levels of
immunoglobulins-M (Ig M) [67].
AMA reactivity is classically studied by immunofluorescence and considered positive at a titre
of ≥1:40 [66]. The targets of the disease-specific ant mitochondrial response are all members of
a family of enzymes, the 2-oxo-acid dehydrogenase complexes and include PDC-E2, branched
chain 2-oxo-acid dehydrogenase complex, and 2-oxo-glutaric acid dehydrogenase complex
[65]. These enzymes catalyse the oxidative decarboxylation of keto acid substrates and are
located in the inner mitochondrial membrane [65].
Patient who had raised ALP and high titre of AMA (tire of ≥ 1:40) or AMA type 2 (M2) can be
diagnosed with PBC without liver biopsy as per EASL (European Association for the Study of
the Liver) guideline [66]. Positive ANA titres are also found in 30–50% of individuals with PBC
(more commonly in the few who are AMA negative), but in this setting ANA reactivity is, in
contrast to AIH, often antigen specific (anti gp-210 and anti sp-100) [12, 68].
Stage Findings
1 (Portal tract Inflammation) Portal tract inflammation from mainly lymphoplasmacytic infiltrates with or without
florid bile duct lesions resulting in septal and interlobular bile ducts.
2 (Peri-portal fibrosis) Gradual increase of peri-portal lesions extending into the hepatic parenchyma-
referred as interface hepatitis.
3 (Bridging fibrosis) Distortion of the hepatic architecture with numerous fibrous septa. Ductopenia
(defined as loss of >50% of interlobular bile ducts) becomes more frequent at this
stage.
4 (Cirrhosis) Cirrhosis with the existence of regenerative nodules.
The stages of PBC are shown in Figure 4.
(Adapted from Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis.
Hepatology 2009;50:291-308)
Table 4. Liver histology stages seen in primary biliary cirrhosis
Liver biopsy is rarely needed in the diagnosis of PBC. However, in patients with overlap of
AIH/PBC might need liver biopsy to access the degree of the liver injury. In PBC, liver histology
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is divided into 4 stages (Table 4, Figure 4). Nowadays, the degree of fibrosis can be determined
by performing non-invasive procedure such as transient elastography or Fibroscan. Magnetic
resonance cholangio-pancreatography (MRCP) and Endoscopic retrograde cholangio-
pancreatography (ERCP) are sometimes required to exclude other biliary pathology or PSC.
Figure above showed lymphocytic cholangitis  
seen in PBC (black arrow). 
Figure above showed peri‐portal (thin arrow) and 
bridging fibrosis (thick arrow) with reticulin stain 
Figure above showed established cirrhosis  
(Haematoxylin Van Gieson stain) 
 
Figure 4. Histology finding of Primary biliary cirrhosis (PBC)
7. Management/treatment
7.1. Standard therapy
7.1.1. Ursodeoxycholic acid (UDCA)
Ursodeoxycholic acid (UDCA) is the only approved treatment for patients with PBC and
shown to be associated with improvement in liver biochemistries, delayed histologic progres‐
sion of disease, and delayed development of oesophageal varices and prolong transplant free
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survival [67, 69]. UDCA at a dose of 13-15 mg/kg is proven benefit. Various risk scores have
been validated to access the response of UDCA in patients with PBC and these are Barcelona,
Paris I and II, Rotterdam and Toronto criteria (table 5) [127-131].
Criteria Biochemical response
Barcelona Decrease of serum ALP > 40% or ALP normalisation (after 1 year)
Paris I ALP ≤ 3 x ULN, AST ≤ 2 x ULN and serum albumin ≤ 1mg/dl (after 1 year)
Paris II ALP and AST < 1.5 x ULN, serum bilirubin <1mg/dl (after 1 year)
Rotterdam Normalisation of abnormal serum bilirubin and/or serum albumin (after 1 year)
Toronto ALP < 1.67 x ULN (after 2 years)
ALP: alkaline phosphatase, AST: Aspartate transaminase, ULN: upper limit of normal
Table 5. Assessment of response to UDCA in patients with PBC
Ursodeoxycholic acid is a hydrophilic bile acid and normally present in about 3% of bile in
humans [70]. In patient with cholestasis, there is a decrease in endogenous production of bile
acids as well as reduction in the absorption of UDCA [70]. After oral administration of UDCA,
it is absorbed in small intestine and colon and transported to liver via portal tract. The
absorption of UDCA is increased after meal consumption due to alkaline pH status. Admin‐
istration of 13-15 mg/kg of UDCA in PBC patients causes enrichment of 40 to 50 % in primary
bile acids [70].
Other drugs have been tested, but none have been found as single agents to be of benefit. These
include chlorambucil, penicillamine, cyclosporine, corticosteroids, azathioprine, mycopheno‐
late mofetil, thalidomide, methotrexate, malotilate, and colchicine [65].
7.1.2. Treatment for fatigue
Fatigue can be difficult to manage and other underlying conditions such as anaemia, thyroid
disorder should be investigated and ruled out. There is no proposed treatment for fatigue and
it can sometime persist even after Liver transplantation. A study by Jones et al showed that
Modafinil at a dose of 100 to 200 mg/day was associated with a significant improvement in
fatigue and improved day time somnolence [71].
7.1.3. Treatment for pruritus
There are few effective treatments available for pruritus in PBC patients. Cholestyramine is a
non-absorbable resin and it is the first line therapy in the management of pruritus. The
recommended dose of cholestyramine is 4 g per dose to a maximum of 16 g/day given 2-4
hours before or after UDCA [65]. In general, cholestyramine is well tolerated, although some
patients report bloating, constipation, and diarrhoea [65].
Rifampicin is a P450 enzyme inducer and used in treatment of pruritus for PBC patients. The
recommended dose is 150 mg once daily or twice daily based on the level of bilirubin. Side
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effects of rifampicin remain a serious concern because cases of hepatitis and hepatic failure,
haemolysis and renal impairment and therefore, patient should be closely monitored during
the treatment [65]. It should not be used together with serotonin reuptake inhibitor (SSRI) in
patient with severe depression since it decrease the effect of SSRI[65].
Opioid antagonist, Naltrexone 50 mg daily, has been shown to be effective in treatment of
pruritus in PBC patients. Other agents are SSRI (sertraline), Etarnacept (TNF-alpha inhibitor),
Amitriptyline, Anti histamine. Some patient with difficult to treat pruritus can be managed
with plasmapheresis.
7.2. Future therapies
Several pilot studies and randomized controlled trials have evaluated various agents in PBC.
Trials with mesenchymal stem cells, Rituximab, Ustekinumab, Moexipril which is an angio‐
tensin-converting enzyme (ACE) inhibitor and Abatacept treatments in PBC is currently
ongoing (www.clinicaltrials.gov).
There is a suggestion that beta retrovirus might be involved in the pathogenesis of PBC and
hence, a randomised controlled trial with lamivudine and zidovudine was studied in PBC
patients [72]. There is a good biochemical response seen in patient taking lamivudine and
zidovudine but complete biochemical normalisation was not observed [72]. The study did not
showed any correlation with virus and biochemical response and as a result, treatment is not
recommended in PBC [72].
Recently, fibrates have been thought to be beneficial in PBC since it has anti-inflammatory
effect via peroxisome proliferator activated receptor alpha (PPAR-a) [67]. Fenofibrate is a fibric
acid and thought to modulate immune response and the cell proliferation and pilot study
which treated 20 patients with fenofibrate and UDCA showed significant improvement in liver
biochemistry (ALP and ALT) and Ig M although albumin and bilirubin remained unchanged
[73]. Larger studies are needed in future. Similar findings were seen in study with bezafibrate.
Obeticholic acid (OCA) is a farnesoid X receptor (FXR) agonist [74]. FXR is expressed in liver,
intestine, adrenal glands and kidneys and has an important role in the enterohepatic circulation
of bile acids [74, 75]. FXR reduces bile acid synthesis by acting on the enzyme cholesterol 7a
hydroxylase and also by down-regulating the expression of the sodium/taurocholate co-
transporting peptide, a bile acid uptake protein[75]. Preliminary studies of OCA in patients
with PBC have demonstrated marked biochemical improvement when administered in
combination with UDCA and alone [74]. Pruritus is the most common side effects and seen at
high dose. Currently, there is a phase 3 trial ongoing for OCA treatment in PBC patients.
8. Prognosis
There are many criteria used to assess biochemical response to UDCA (Table 5). The 1-year
biochemical response to UDCA provides significant prognostic information even in the early
stage of PBC [70]. Early-stage patients who show ALP and AST ฀1.5× upper limit of normal
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(ULN), and normal bilirubin level after 1 year of treatment appear to be at very low or no risk
of liver failure or progression to cirrhosis. In those patients, they had a 10-year transplant-free
survival rate of 90% compared to 51% for those who did not (p <0.001) [76]. About 40% of
patients have a suboptimal response to UDCA and subsequently need additional therapy.
Liver transplantation is the treatment for patients with decompensated liver cirrhosis and
recurrence of PBC is seen in 20% after LT [77].
9. Primary sclerosing cholangitis
9.1. Epidemiology
Primary sclerosing cholangitis (PSC) is a rare autoimmune liver disease and primary affects
larger bile ducts. It is caused by chronic inflammation which then leads to fibrotic strictures
and dilatation of hepatic biliary system and leading to chronic cholestasis. Chronic cholestasis
can subsequently lead to liver cirrhosis with portal hypertension and liver failure [78]. PSC
can affect any part of the biliary system including the gallbladder [78].
It is more common in male with median age of around 40 and affects mostly Northern
European descendants [79]. The most important underlying risk factor associated with PSC is
inflammatory bowel disease and PSC is seen in 75 % of cases of patients with IBD [79]. Around
60 to 80% of patients with PSC have underlying ulcerative colitis, mainly on the right side of
the colon and 4% of patients with UC have co-existing PSC [80].
A recent study in UK showed the incidence of PSC to be 0.41 cases per 100,000 populations [81],
although the true incidence may be underestimated since it is a relatively rare diseases and
needs expertise and invasive procedures to make the diagnosis [79].
9.2. Pathogenesis
The exact mechanism of pathogenesis in PSC is unknown but thought to be multifactorial. It
has thought that PSC occurs in individuals with genetic predisposition triggers various
environmental stimuli [80]. Patient who has first degree relative with PSC have 9 to 39 fold
increased risk of developing PSC and the most associated HLA are HLA DRB1 and DRQ1 [80].
Gut and liver axis theory had been proposed in the pathogenesis of PSC [82]. Manipulation of
the intestinal micro flora changes the immune and metabolic pathway [83]. There has been
hypothesized that translocation of microbial flora across the inflamed, permeable gut via the
portal system to liver and biliary system activate the immune system and cause inflammation
of the biliary tree [84-86]. Homing of mucosal lymphocytes which possess (C-C motif chemo‐
kine receptor-9) CCR9 and alpha4beta7 in the liver leads to biliary damage in PSC [87, 88].
Recently mucosa associated innate T cells and innate lymphoid cells has been proposed in the
pathogenesis of PSC [89]. Although the putative gut-derived trigger(s) of hepatobiliary
pathobiology in PSC has not been determined, microbial metabolites or products (i.e.,
pathogen-associated molecular patterns, PAMPs) such as lipopolysaccharide (i.e., endotoxin,
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LPS) and peptidoglycan (i.e., a bacterial cell wall polymer, PG) have been proposed as likely
candidates [90].
9.3. Clinical presentations and diagnosis
About 15-40% of patients are asymptomatic during the early stage of the clinical course and
at later stage, the most common symptoms are jaundice, pruritus, fatigue and abdominal pain
[79]. Any patient who has underlying IBD and abnormal liver blood tests especially raised
ALP should be investigated for PSC. In 95 % of cases, ALP rose 3-10 times the upper limit of
normal and other liver enzymes ALT and AST were 2-3 times above the normal limit [79].
Bilirubin tends to be within normal range in about 60% of patients. In 69-95% of patients with
PSC, 50 to 80% of patients with UC and 10-20% of patients with Crohn’s colitis have positive
perinuclear antineutrophil autoantibodies (pANCA) [79].
Mayo risk score is used in PSC and the score is calculated using age, bilirubin, albumin, liver
transaminase, AST and varcieal bleed and it is used to estimate survival of patient with PSC
for up to 4 years [132]. The Mayo Risk Score= (0.0295 * (age in years)) + (0.5373 * (total bilirubin
in mg/dL)) - (0.8389 * (serum albumin in g/dL)) + (0.5380 * (AST in IU/L) + (1.2426 * (points for
variceal bleeding; 0= No, 1=Yes)). The score of less than or equal to zero is regarded as low
risk, between 0 and 2 as intermediate and above 2 as high risk groups.
The diagnosis is best confirmed by MRCP, which is a non-invasive and first line investigation
for the diagnosis of PSC. ERCP is used mainly for therapeutic purposes such as stenting,
balloon dilatation and biliary brushing in patient with PSC. Contrast cholangiography, which
reveals characteristic features of diffuse, multifocal strictures and focal dilation of the bile
ducts, leading to a beaded appearance [79]. Liver biopsy is rarely necessary due to good
diagnostic yield with MRCP or ERCP investigations except in suspicion of small duct PSC or
overlap with AIH. Periductal concentric (“onion-skin”) fibrosis is a classic histopathologic
finding of PSC, but this observation is infrequent in PSC [91] (Figure 5).
Figure above showed early sign of PSC: peri‐ductal 
fibrosis (black arrow). 
Figure above showed late stage of PSC with fibro‐
obliterative duct lesion, in which the bile duct is 
completely filled with fibrosis (large arrow)
 
Figure 5. Histology findings in Primary Sclerosing Cholangitis (PSC)
Autoimmunity - Pathogenesis, Clinical Aspects and Therapy of Specific Autoimmune Diseases114
In addition to biliary cirrhosis, complications of PSC include dominant strictures of the bile
ducts, cholangitis, cholangiocarcinoma, colon dysplasia and cancer in patients with IBD,
gallbladder polyps, gallbladder cancer, and hepatic osteodystrophy [79]. Cholangitis occurs
in 10 to 15 % of patients with PSC [80]. The cumulative lifetime risk for cholangiocarcinoma
in PSC is estimated at 7 to 15% [67]. About half of those cholangiocarcinomas are diagnosed
within one year of PSC diagnosis and the rate of cancer development is 0.5 to 1.5% per year
subsequently after the first year[67]. Suspected dominant stricture should be investigated by
Endoscopic ultrasound scan (EUS) and biopsy along with Positron Emission Tomography
(PET) scan.
Immunoglobulin G4 (Ig-G4) associated cholangitis is similar to PSC and is characterized by
the presence of biliary strictures, lymphoplasmacytic infiltration and elevated Ig G4 serum
levels [92]. Ig G4 elevation is seen in 12% of PSC patients [92]. The biliary features are similar
on the cholangiogram in these two conditions and hence, it is important to check Ig G4 level
and review the anatomy of pancreas on imaging. Tissue from liver biopsy can be stained using
monoclonal anti-human IgG4 antibody. It is important to differentiate between the two
because Ig G4 associated cholangitis or pancreatitis responsive to steroids unlike PSC.
10. Management/treatment
10.1. Standard therapy
To date, there are no effective therapies for patients with PSC and the only treatment for end
stage PSC is liver transplantation. Timing for liver transplantation is challenging in PSC as
these patients sometimes do not fulfil MELD criteria MELD criteria but they can deteriorate
rapidly thus early referral to experience centres is essential. UDCA has been used in cholestatic
patients with PSC although the data suggested that the medication has not improved overall
survival. Studies utilizing doses between 10–15 mg/kg/day were associated with biochemical
and histologic improvement [93, 94]. Two previous studies looking at high dose UDCA at a
dose of 17-23 mg/kg/day [95] and 28-30 mg/kg/day [96, 97] showed that there were no
difference in mortality or LT but increased in adverse events. A recent meta-analysis found no
difference in fatigue, mortality, histologic progression or development of cholangiocarcinoma
for standard or high dose UDCA [92, 98] and therefore, high dose UDCA is not used in routine
clinical practice.
Antibiotics are used in patients with biliary sepsis in the background of PSC and some
clinicians used rotating antibiotics in patients with resistant bacteremia. Published data
looking into vancomycin or metronidazole treatment suggests that both are efficient in
treatment of infection but vancomycin achieved improvement in ALT more than metronida‐
zole with less side effects [99]. A recent randomised pilot study of vancomycin or metronida‐
zole treatment in PSC patients showed that both antibiotics are effective although only
vancomycin group reached the primary end point of reduction in ALP at 12 weeks [99].
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10.2. Future therapies
There are many ongoing clinical trials in PSC such as obeticholic acid, mitomycin, thalidomide,
LUM001: an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), GS-6624: a
Monoclonal Antibody against Lysyl Oxidase like 2 (LOXL2), Xifaxan, Cladribine and the
combination of UDCA and all trans-retinoid acid (ATRA) (www.clnicaltrial.gov). There are
ongoing phase 1 and 2 trials on anti-fibrotic therapies in PSC.
11. Overlap syndrome
The term ‘overlap syndrome’ described co-existence of AIH with features of PBC or PSC [12].
The diagnosis can be challenging and there is no single test available to diagnose. Therefore,
it is important to revisit clinical history or repeat investigation if there is in doubt with the
diagnosis. The diagnosis can be made with combination of tests such as blood biochemistry,
immunology with addition of radiology and tissue biopsy. It is assumed that overlap syn‐
drome can be found in 5-20% of cases [12].
11.1. AIH/PBC overlap
AIH/PBC should be considered in patients with mixed pattern of cholestastic and hepatitis
features or anyone with suboptimal response to immunosuppressions. It has been reported
that AIH/PC occurs in 8% of patients with either AIH or PBC. Some PBC patients express
negative AMA with positive ANA serology or SMA serology and hence, diagnosis based on
immunology alone can be tricky. In general, IgG elevation is common in AIH and IgM is manly
observed in PBC. Treatment should be targeted both AIH and PBC in these patients.
11.2. AIH/PSC overlap
In adults with both AIH and IBD, cholangiographic changes suggestive of PSC are present in
up to 44% patients and may affect therapy and prognosis [13]. Those who develop AIH during
childhood or Autoimmune sclerosing cholangitis are most common to develop into AIH/PSC
overlap. MRCP and repeat liver biopsy is recommended. Treatment should be directed
towards PSC and immunosuppression should be slowly weaned off unless they are indicated
for inflammatory bowel disease.
12. Liver Transplantation (LT)
Liver transplantation (LT) is the treatment for patients with end stage AIH, PBC or PSC disease.
The common indications are decompensated liver cirrhosis as indicated by the presence of
refractory or resistant ascites, hepatic encephalopathy or uncontrolled variceal bleeding.
Hepatocellular carcinoma, hepatopulmonary syndrome and portopulmonary hypertension
are the other indications for LT. Model for End Stage Liver Disease (MELD) score is calculated
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by using renal function (Creatinine), International Normalised ratio (INR) and Bilirubin.
MELD score= [0.957x Loge (creatinine in mg/dL) + 0.378x Loge (bilirubin in mg/dL) + 1.120x
Loge (INR) + 0.643) [133]. Patients with MELD score of above 16 with other indication is
considered for liver transplant assessment. MELD score was initially developed to predict
survival in patients undergoing Trans jugular Porto systemic shunt [100, 101]. In 2002, UNOS
(the United Network of Organ Sharing) adapted a new approach to allocate organ giving
priority to the sickest patient and the assessment is based on MELD score [102]. Implementa‐
tion of MELD in 2002 led to an immediate reduction in LT waiting list registrations for the first
time in history of LT (12% decrease in 2002) [103] as well as reduction in mortality on the
waiting list [104].
Since 1996, listing for transplantation in the United Kingdom was based on the following
principles: selecting patients if the expected survival without transplantation was 1 year or
less or liver disease that was associated with an unacceptable quality of life and expecting that
patients would have an at least 50% survival at 5 years with acceptable quality of life [105].
Serum sodium was associated with a higher risk of mortality independent of the MELD score
in patients listed for orthotropic liver transplantation [106]. In United Kingdom, UKLED score
(United Kingdom End Stage Liver Disease has been used since 2008 and it is calculated from
patient’s INR, serum creatinine, serum bilirubin and serum sodium) has been used in assess‐
ment of liver transplantation. UKELD score of 49 is the baseline entry criteria for LT assess‐
ment. Patients with UKELD score of 49 have 9% one year mortality and score above 60 has
mortality of 50% [105].
LT is required in about 10% of patients with AIH and in Europe; 4-6 % of LT are for the
indication of AIH [2, 7]. Long-term survival is excellent in AIH patients with 5 year survival
being up to 92 % [2]. Recurrence of AIH can occur post LT and the rate of recurrence is between
8-12 % at year 1 and higher after 5 years follow up with the rate of around 36-65% [107]. The
treatment should be either increase with the ongoing immunosuppressive therapies or change
to alternative therapies such as addition of MMF, replacement of tacrolimus with cyclosporine
or the replacement of calcineurin inhibitor (CNI) with sirolimus [108].
In  patients  with  PBC,  LT  is  indicated  for  decompensated  liver  cirrhosis,  hepatocellular
carcinoma  and  intractable  pruritus  with  unacceptable  quality  of  life.  Patient  should  be
referred for LT assessment when the bilirubin reaches around 100 umol/L with MELD >12
and Mayo risk score of 7-8 [134]. PBC can recur in post LT and the median time is 3 to 5.5
years although it can happen within the first year of transplantation [108]. PBC recurs in
15 to 30% of patients after LT and most of the patients do not lose their graft [67].  The
treatment of recurrence PBC is UDCA, which causes improvement with ALP and ALT but
not the patient or graft survival [109].
In addition to above mentioned indication for LT, some patients with PSC will need LT due
to intractable pruritus, recurrent cholangitis in the presence of dominant bile duct strictures
that cannot be managed endoscopically and the presence of limited stage cholangiocarcinoma
[108]. 5 year survival post LT is around 80%[92]. Recurrence of PSC have been documented
among LT recipients and its prevalence ranges from 15 to 30% and the median time for
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recurrence is between 3 and 5 years post LT [108] and can be associated with poor survival
and graft loss [67].
13. De novo autoimmune hepatitis post LT
De novo autoimmune hepatitis (d-AIH) in LT patients whom were transplanted for other
reasons than AIH was documented in late 1990 [110]. De novo autoimmune hepatitis occurs in
1-7 % of patients 0.1-9 years after transplantation, especially in children [135]. Risk factors for
de novo-AIH had been associated with older age donor, female donor, acute cellular rejection
and the use of tacrolimus [111, 112]. The disease is usually characterized by features of acute
hepatitis  in otherwise stable transplant  recipients.  The characteristic  feature is  a  marked
hypergammaglobulinaemia with positive ANA. Antibodies against glutathione S-transferase
T1 (GSTT1) has been reported in patients with de novo immune hepatitis following liver
transplantation, thus suggesting that immune system recognizes the Glutathione S-transfer‐
ase theta-1 (GSTT1) protein as a non-self-antigen, and mount an allo-reactive immune re‐
sponse  and  molecular  mimicries  that  override  self-tolerance[113].  Antibodies  against
cytokeratin  8/18  in  patient  with  de  novo  autoimmune  hepatitis  after  living-donor  liver
transplantation had also been reported thus the changes in cytokeratin 8/18 in hepatocytes might
be one of the sources of pathogenesis of de novo autoimmune hepatitis after liver transplanta‐
tion[114]. A histologic pattern of centri-lobular injury including increased necroinflammatory
activity and increased plasma cell infiltration correlates with measurements of autoimmunity
in de novo AIH recipients [115]. Treatment with increased dose of steroids or Azathioprine
results in an improved outcome. However, maintenance therapy is usually required [116].
Standard liver tests do not reflect the extent of these changes, so protocol liver biopsies may be
required to detect these changes [117].
14. Pregnancy and AILD
Pregnancy constitutes a major challenge to the maternal immune system. AIH tends to improve
after the second trimester of pregnancy, allowing a decrease in immunosuppressive therapy.
It is due to a variety of immunological alterations that are induced by pregnancy in order to
protect the semi-allogeneic fetus from rejection. Immuno-regulation induced by pregnancy
polarizes the immune system to T-Helper (TH)-2 predominant phenotype. The increase of
circulating inhibitors of pro-inflammatory cytokines occurring in pregnancy could act as a
potent anti-inflammatory agent in AIH. T regulatory (Treg) cells are a recently discovered subset
of T-lymphocytes with potent suppressive activity and pivotal roles in curtailing destructive
immune responses  and preventing autoimmune disease[118].  Systemic  expansion of  the
maternal T suppressor or CD4+CD25+ regulatory T cell pool during pregnancy suppress an
aggressive allogeneic response directed against the fetus[119].
Premature birth is the greatest risk and fetal mortality is reported to be around 21%, perinatal
mortality is 4% and maternal mortality is 3% [14]. Poor disease control in the year prior to
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pregnancy and the absence of drug therapy are associated with poor outcomes [120]. Adverse
pregnancy outcomes were highly associated with the presence of antibodies against soluble
liver antigen/liver-pancreas (SLA/LP) and Ro/SSA [121] Preconception advice and discussion
is important and should be emphasised. More than half of the women reduced or stopped the
immune suppression during pregnancy or breastfeeding. AZA is a Food and Drug Adminis‐
tration (FDA) category D drug and safety in pregnancy has not been well established in human
studies [14] however, current pharmacological treatment including azathioprine appears to
be safe during pregnancy and lactation. There are no reported increased in congenital
malformations with AZA and it is safe to use in mother who plan to breast-feed the baby. AIH
commonly exacerbates following delivery [122, 123] and therefore, vigilance is required during
the postpartum period. Patients with AIH need to be monitored carefully during pregnancy
and for several months post partum [124]. Women with advance cirrhosis and portal hyper‐
tension have an increased risk of variceal bleed during the pregnancy and therefore, eradica‐
tion of varices either with banding or pharmaco-therapy are recommended prior to conception.
Pregnant women with cirrhosis and portal hypertension should undergo upper GI endoscopy
during the second trimester and careful discussion with obstetric team and fetal medicine team
is required for the safety of mother and the baby.
There are limited data for pregnancy and PBC. It has been noted that early diagnosis of PBC
and early used of UDCA have a favourable outcomes on the pregnancy [125]. PSC rarely occur
in female but the condition does not seem to reduce fertility in both men and women according
to case series [126].
15. Conclusion
AILD is a spectrum of autoimmune condition mainly affecting liver (in the case of AIH) and
biliary system (in PBC and PSC). The diagnosis is guided by clinical, biochemical and immu‐
nological parameters, although liver biopsy is still useful especially in patients with AIH to
diagnose as well as for the assessment and monitoring of the disease status. In AIH, the aim
of the treatment is to suppress the immune system with long term immunosuppressive
medications such as azathioprine. There are new therapies emerging on the horizon. In PBC,
women are more affected and the current treatment used is UDCA although there are many
trials running ongoing in the treatment of PBC and it is an exciting era. For PSC, the definitive
treatment is liver transplantation and more research is needed to understand that pathogenesis
and treatment in this field of subject.
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